Zealand to bet on niche markets
Zealand Pharma CEO Britt Meelby Jensen will use licensing profits from the Sanofi collaboration to take the company's own portfolio even further within a series of niche areas. She is not worried about a Korean player's impact on the lucrative Sanofi deal.
BY STEFAN SINGH KAILAY
CEO Britt Meelby Jensen describes her company's third quarter results as "devoid of any major surprises."
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand CEO: We are obligated to be ambitious
For abonnenter
Analyst: Novo’s product is superior, but…
For abonnenter
Zealand chief is pleased with quiet quarter
For abonnenter
